Technological advancements and increased clarity of viral replication mechanism paves way for RNAi therapeutics for the cure of viral diseases, says RNCOS.
(prHWY.com) February 25, 2013 - NOIDA, India -- As per the new research report by RNCOS, "Global RNAi Market Analysis", RNAi drugs are finding increasing research focus for the treatment of viral infections. Few RNAi drugs in pipeline hold immense potential. For instance, in February 2012, Tekmira Pharmaceuticals initiated the TKM-Ebola Phase 1 clinical trial, which is a placebo-controlled, single-blind, single-ascending dose study with additional multiple-ascending dose cohorts of its RNAi drug "TKM-Ebola" in healthy human volunteers.
TKM-Ebola is being developed under specific FDA regulatory guidelines called the Animal Rule. The Animal Rule provides that under certain circumstances, where it is unethical or not feasible to conduct human efficacy studies, the FDA may grant marketing approval based on adequate and well controlled animal studies when the results of those studies establish that the drug is reasonably likely to produce clinical benefit in humans. This has been done keeping in view the immense potential of the TKM-Ebola that has for the cure of widely prevalent Ebola virus infections.
The global RNAi market is showing robust research activities and promising growth. It presents an extensive potential in multiple areas, such as drug discovery, drug development, and therapeutic applications for various indications, and aids in the basic research. Our latest research found that various components, such as siRNA & miRNA possess immense opportunities and provide a wide range in different drug classes. These molecules also find wide applications in sectors, such as functional genomics, disease diagnostics, and agriculture, among others. It is anticipated that the global RNAi market will grow stupendously at a CAGR of around 17% during 2011-2015.
Overall, the report provides a clear understanding of the RNAi market and its current status, globally. Recent industry activities in key geographies, such as US, Europe, and Asia-Pacific regions have been covered in this report. Products and services of key market players along with brief information about their businesses have also been provided. The report also covers a detailed analysis on therapeutics in the pipeline, and expected to evolve enormously in the future. An analysis of the key market trends and key competitor analysis provides a holistic understanding to the reader on the industry's current state.
For FREE SAMPLE of this report visit:
http://www.rncos.com/Report/IM329.htm
Some of our Related Reports are:
- Cancer Monoclonal Antibodies Market to 2015 (
http://www.rncos.com/Report/IM375.htm)
- Global Biosimilars Market Forecast to 2015 (
http://www.rncos.com/Report/IM379.htm)
- US Biotech Market Analysis (
http://www.rncos.com/Report/IM0300.htm)
- Global miRNA Market Outlook (
http://www.rncos.com/Report/IM286.htm)
- Global HIV Therapeutics Market Analysis (
http://www.rncos.com/Report/IM361.htm)
Check Related REPORTS on:
http://www.rncos.com/Healthcare_Industry.htm
About RNCOS
RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.
###